Novomix 30 (Pen) is a Fixed-Dose Combination (FDC) Drug Brand being manufactured and marketed by Novo Nordisk India Pvt Ltd.. This medicine is combination of more than one active ingredient or substance within a single pharmaceutical form type. The main active ingredients or salts in this drug are Insulin (Analogue) Aspart, Insulin (Analogue) Aspart Protamine. This drug comes in the form of Pen. The general packing available for this medicine consists of 3 ml and is priced at Rs 555.74 (arround $7.78036 US Dollar)
The main active ingredients or salts in Novomix 30 (Pen) are :
Insulin (Analogue) Aspart-30%/100 iu
Insulin (Analogue) Aspart Protamine-70%/100 iu
Insulin (Analogue) Aspart Indication (Prescribed for or used as):
For more details on Insulin (Analogue) Aspart, its Indication, Prescription, Usage, Dosage, Precaution, Side Effects etc, please check : Insulin (Analogue) Aspart..
Insulin (Analogue) Aspart Protamine Indication (Prescribed for or used as):
For more details on Insulin (Analogue) Aspart Protamine, its Indication, Prescription, Usage, Dosage, Precaution, Side Effects etc, please check : Insulin (Analogue) Aspart Protamine..
Novomix 30 (Pen) Drug Brands Substitutes with similar Fixed-Dose Combination (FDC) :
There are 1 Fixed-Dose Combination (FDC) Drug Brands listed here as Substitutes for Novomix 30 (Pen), which have same Fixed-Dose Combination of active substances or ingredients (i.e. Insulin (Analogue) Aspart-30%/100 iu Insulin (Analogue) Aspart Protamine-70%/100 iu). Please note that one can request a doctor or pharmacist to substitute a FDC Brand Version of the prescribed FDC drug brand, if any. Fixed-Dose Combination Drugs are being increasingly used due to the benefit of the combined effects of active ingredients given together. However, it is necessary to investigate the possible benefits in the clinical situation against possible disadvantages for each fixed combination drug and for each dose of the fixed combination drug. Potential advantages of fixed combination drugs may also include the counteracting by one ingredient of an adverse reaction produced by another one, and simplification of therapy, leading to improved compliance.